Authors:
Muhammad Shafiq Department of Microbiology, Quaid-e-Azam University, Islamabad, Pakistan

Search for other papers by Muhammad Shafiq in
Current site
Google Scholar
PubMed
Close
,
Dr. Hazir Rahman Department of Microbiology, Kohat University of Science and Technology, Kohat, Pakistan

Search for other papers by Dr. Hazir Rahman in
Current site
Google Scholar
PubMed
Close
,
Muhammad Qasim Department of Microbiology, Kohat University of Science and Technology, Kohat, Pakistan

Search for other papers by Muhammad Qasim in
Current site
Google Scholar
PubMed
Close
,
Najma Ayub Department of Microbiology, Pakistan Institute of Medical Sciences, Islamabad, Pakistan

Search for other papers by Najma Ayub in
Current site
Google Scholar
PubMed
Close
,
Shagufta Hussain Department of Microbiology, Quaid-e-Azam University, Islamabad, Pakistan

Search for other papers by Shagufta Hussain in
Current site
Google Scholar
PubMed
Close
,
Jafar Khan Department of Microbiology, Kohat University of Science and Technology, Kohat, Pakistan

Search for other papers by Jafar Khan in
Current site
Google Scholar
PubMed
Close
, and
Madiha Naeem Department of Microbiology, Kohat University of Science and Technology, Kohat, Pakistan

Search for other papers by Madiha Naeem in
Current site
Google Scholar
PubMed
Close
Restricted access

Abstract

Enterobacteriaceae produces AmpC β-lactamases that make them resistant to commonly used antibiotics. AmpC β-lactamases can be chromosomal-mediated or plasmid-mediated AmpC β-lactamases (PABLs). The present study was undertaken to determine the occurrence of PABLs production in clinical isolates in Escherichia coli and Klebsiella pneumoniae.

Among 1328 culture positive samples, 511 isolates were identified as E. coli (81.02%, n = 414) and K. pneumonia (18.98%, n = 97). Cefoxitin resistance was observed in E. coli (19.57%, n = 81) and K. pneumoniae (22.68%, n = 22). Out of these cefoxitin resistant isolates, 40.74% (n = 33) E. coli and 54.55% (n = 12) K. pneumoniae came out to be PABL producers. Prevalence of both PABLs and ESBLs in E. coli and K. pneumoniae was 29.24% (n = 8) and 47% (n = 5), respectively. Isolates coproducing PABLs and ESBL exhibited increased minimum inhibitory concentrations (MICs) for selected cephalosporins. This study documented a high frequency of PABLs producing isolates from hospital which may lead to serious therapeutic problem.

  • 1. MA Leverstein-van Hall HE Blok A Paauw AC Fluit A Troelstra EM Mascini 2006 Extensive hospital-wide spread of a multidrug-resistant Enterobacter cloacae clone, with late detection due to a variable antibiogram and frequent patient transfer J Clin Microbiol 44 518 524.

    • Search Google Scholar
    • Export Citation
  • 2. K Eggleston R Zhang RJ Zeckhauser 2007 The global challenge of antimicrobial resistance: insights from economic analysis Int J Environ Res Public Health 7 3141 3149.

    • Search Google Scholar
    • Export Citation
  • 3. R Zhang K Eggleston V Rotimi RJ Zeckhauser 2006 Antibiotic resistance as a global threat: evidence from China, Kuwait and the United States Global Health 2 6.

    • Search Google Scholar
    • Export Citation
  • 4. K Bush GA Jacoby 2010 Updated functional classification of beta-lactamases Antimicrob Agents Chemother 54 969 976.

  • 5. H Kanamori RB Navarro H Yano LT Sombrero MR Capeding SP Lupisan 2011 Molecular characteristics of extended-spectrum beta-lactamases in clinical isolates of Enterobacteriaceae from the Philippines Acta Trop 120 140 145.

    • Search Google Scholar
    • Export Citation
  • 6. GA Jacoby LS Munoz-Price 2005 The new beta lactamases N Engl J Med 380 391.

  • 7. G Peirano 2008 Multi resistant Enterobacteriaceae new threat to an old prob; expect review of anti infective therapy Expert Rev Anti Infect Ther 6 657 669.

    • Search Google Scholar
    • Export Citation
  • 8. WM Kirby GM Yoshihara KS Sundssted JH Warren 1956 Clinical usefulness of a single disc method for antibiotic sensitivity testing Antibiot Annu 892 897.

    • Search Google Scholar
    • Export Citation
  • 9. JA Black ES Moland KS Thomson 2005 AmpC disk test for detection of plasmid-mediated AmpC beta-lactamases in Enterobacteriaceae lacking chromosomal AmpC beta-lactamases J Clin Microbiol 43 3110 3113.

    • Search Google Scholar
    • Export Citation
  • 10. S Singhal T Mathur S Khan DJ Upadhyay S Chugh R Gaind 2005 Evaluation of methods for AmpC beta-lactamase in gram negative clinical isolates from tertiary care hospitals Indian J Med Microbiol 23 120 124.

    • Search Google Scholar
    • Export Citation
  • 11. V Jarlier M Nicolas G Fournier A Phillipon 1988 ESBLs conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae; hospital prevalence and susceptibility patterns Rev Infect Dis 10 867 878.

    • Search Google Scholar
    • Export Citation
  • 12. ClinicalLaboratory Standards Institute CLSI 2010 Performance standards for antimicrobial susceptibility testing Clinical and Laboratory Standards Institute Wayne, PA.

    • Search Google Scholar
    • Export Citation
  • 13. ClinicalLaboratory Standards Institute CLSI 2006 Quality control minimal inhibitory concentration (MIC) limits for broth microdilution and MIC interpretive breakpoints Clinical and Laboratory Standards Institute Wayne, PA.

    • Search Google Scholar
    • Export Citation
  • 14. A Philippon G Arlet GA Jacoby 2002 Plasmid-determined AmpC-type beta-lactamases Antimicrob Agents Chemother 46 1 11.

  • 15. H Afreenish U Javaid K Fatima O Maria K Ali I Muhammad 2011 Frequency and antibiotic susceptibility pattern of Amp C beta-lactamase producing bacteria isolated from a tertiary care hospital of Rawalpindi, Pakistan Pak J Med Scie 27 578 581.

    • Search Google Scholar
    • Export Citation
  • 16. PC Schreckenberger 2004 Conundrums in the laboratory detection of antimicrobial resistant Gram-negative bacteria Rev Med Microbiol 15 45 49.

    • Search Google Scholar
    • Export Citation
  • 17. M Tumbarello M Sali EM Trecarichi F Leone M Rossi B Fiori 2008 Bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy Antimicrob Agents Chemother 52 3244 3252.

    • Search Google Scholar
    • Export Citation
  • 18. KB Laupland DL Church J Vidakovich M Mucenski JD Pitout 2008 Community-onset extended-spectrum beta-lactamase (ESBL) producing Escherichia coli: importance of international travel J Infect 57 441 448.

    • Search Google Scholar
    • Export Citation
  • 19. MA Pfaller HS Sader TR Fritsche RN Jones 2006 Antimicrobial activity of cefepime tested against ceftazidime-resistant Gram-negative clinical strains from North American Hospitals: report from the SENTRY Antimicrobial Surveillance Program (1998–2004) Diagn Microbiol Infect Dis 56 63 68.

    • Search Google Scholar
    • Export Citation
  • 20. W Song ES Moland ND Hanson JS Lewis JH Jorgensen KS Thomson 2005 Failure of cefepime therapy in treatment of Klebsiella pneumoniae bacteremia J Clin Microbiol 43 4891 4894.

    • Search Google Scholar
    • Export Citation
  • 21. H Ding Y Yang Q Lu Y Wang Y Chen L Deng 2008 The prevalence of plasmid-mediated AmpC beta-lactamases among clinical isolates of Escherichia coli and Klebsiella pneumoniae from five children's hospitals in China Eur J Clin Microbiol Infect Dis 27 915 921.

    • Search Google Scholar
    • Export Citation
  • 22. KS Thomson DA Weber CC Sanders WE Sanders Jr. 1990 Beta-lactamase production in members of the family Enterobacteriaceae and resistance to beta-lactam-enzyme inhibitor combinations Antimicrob Agents Chemother 34 622 627.

    • Search Google Scholar
    • Export Citation
  • 23. V Gupta P Datta N Agnihotri J Chander 2006 Comparative in vitro activities of seven new beta-lactams, alone and in combination with beta-lactamase inhibitors, against clinical isolates resistant to third generation cephalosporins Braz J Infect Dis 10 22 25.

    • Search Google Scholar
    • Export Citation
  • Collapse
  • Expand
The author instructions are available in PDF.
Please, download the file from HERE.

 

Senior editors

Editor(s)-in-Chief: Dunay, Ildiko Rita

Editor(s)-in-Chief: Heimesaat, Markus M.

Editorial Board

  • Berit Bangoura (University of Wyoming, USA)
  • Stefan Bereswill (Charité - University Medicine Berlin, Germany)
  • Dunja Bruder (University of Magdeburg, Germany)
  • Jan Buer (University of Duisburg, Germany)
  • Edit Buzas (Semmelweis University, Hungary)
  • Renato Damatta (UENF, Brazil)
  • Maria Deli (Biological Research Center, HAS, Hungary)
  • Olgica Djurković-Djaković (University of Belgrade, Serbia)
  • Jean-Dennis Docquier (University of Siena, Italy)
  • Zsuzsanna Fabry (University of Washington, USA)
  • Ralf Ignatius (Charité - University Medicine Berlin, Germany)
  • Achim Kaasch (Otto von Guericke University Magdeburg, Germany)
  • Oliver Liesenfeld (Inflammatix, USA)
  • Matyas Sandor (University of Wisconsin, USA)
  • Ulrich Steinhoff (University of Marburg, Germany)
  • Michal Toborek (University of Miami, USA)
  • Susanne A. Wolf (MDC-Berlin, Germany)

 

Dr. Dunay, Ildiko Rita
Magdeburg, Germany
E-mail: ildiko.dunay@med.ovgu.de

Indexing and Abstracting Services:

  • PubMed Central
  • Scopus
  • ESCI
  • CABI
  • CABELLS Journalytics

 

2022  
Web of Science  
Total Cites
WoS
717
Journal Impact Factor 2.2
Rank by Impact Factor

n/a

Impact Factor
without
Journal Self Cites
2.2
5 Year
Impact Factor
2.8
Journal Citation Indicator 0.66
Rank by Journal Citation Indicator

Microbiology (Q2)

Scimago  
Scimago
H-index
11
Scimago
Journal Rank
0.614
Scimago Quartile Score Microbiology (Q3)
Microbiology (medical) (Q3)
Immunology and Allergy (Q3)
Immunology (Q3)
Scopus  
Scopus
Cite Score
8.3
Scopus
CIte Score Rank
Microbiology 33/163 (80th PCTL)
Microbiology (medical) 28/124 (77th PCTL)
Immunology and Allergy 63/211 (70th PCTL)
Immunology 69/217 (68th PCTL)
Scopus
SNIP
1.221

 

2021  
Web of Science  
Total Cites
WoS
790
Journal Impact Factor not applicable
Rank by Impact Factor not applicable
Impact Factor
without
Journal Self Cites
not applicable
5 Year
Impact Factor
not applicable
Journal Citation Indicator 0,64
Rank by Journal Citation Indicator Microbiology 81/157
Scimago  
Scimago
H-index
not indexed
Scimago
Journal Rank
not indexed
Scimago Quartile Score not indexed
Scopus  
Scopus
Cite Score
not indexed
Scopus
CIte Score Rank
  not indexed
Scopus
SNIP
not indexed

2020  
CrossRef Documents 23
WoS Cites 708
Wos H-index 27
Days from submission to acceptance 219
Days from acceptance to publication 176
Acceptance Rate 70%

2019  
WoS
Cites
558
CrossRef
Documents
24
Acceptance
Rate
92%

 

European Journal of Microbiology and Immunology
Publication Model Gold Open Access
Submission Fee none
Article Processing Charge 600 EUR/article
Regional discounts on country of the funding agency World Bank Lower-middle-income economies: 50%
World Bank Low-income economies: 100%
Further Discounts Editorial Board / Advisory Board members: 50%
Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100%
Subscription Information Gold Open Access
Purchase per Title  

European Journal of Microbiology and Immunology
Language English
Size A4
Year of
Foundation
2011
Volumes
per Year
1
Issues
per Year
4
Founder Akadémiai Kiadó
Founder's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 2062-509X (Print)
ISSN 2062-8633 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Dec 2023 28 1 0
Jan 2024 17 4 0
Feb 2024 13 1 0
Mar 2024 16 0 0
Apr 2024 11 0 0
May 2024 14 0 0
Jun 2024 4 0 0